STOCK TITAN

Insulet Corp - PODD STOCK NEWS

Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.

Insulet Corporation (PODD) delivers innovative diabetes management solutions through its flagship Omnipod® insulin pump system. This page aggregates official news and developments about the company's medical device innovations, financial performance, and strategic initiatives.

Investors and healthcare professionals will find timely updates including quarterly earnings reports, product launch announcements, regulatory milestones, and partnership agreements. All content is sourced directly from verified corporate communications to ensure accuracy.

Key coverage areas include FDA clearances for new devices, clinical study results, international market entries, and technology partnerships enhancing insulin delivery systems. The resource is particularly valuable for tracking advancements in tubeless pump technology and automated insulin dosing integrations.

Bookmark this page for streamlined access to Insulet's latest developments in diabetes care innovation. Check regularly for updates that may impact long-term growth strategies or patient care standards.

Rhea-AI Summary

Insulet (NASDAQ: PODD) reported a 23% year-over-year revenue increase in the first quarter of 2024, with total revenue reaching $441.7 million. The Company exceeded its guidance range due to revenue outperformance across all product lines. Gross margin increased to 69.5%, operating income rose to $56.9 million, and net income reached $51.5 million. Insulet also achieved strong new customer starts, expanded market share globally, and launched new products like Omnipod 5 integrated with Dexcom's G7 sensor. The company is raising its full-year revenue and operating margin guidance for 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
-
Rhea-AI Summary

Insulet (NASDAQ: PODD) released its 2023 Sustainability Report highlighting achievements in environmental, social, and governance areas. The report focuses on product accessibility, responsible growth, affordability, resilient operations, and sustainable product innovation. Insulet reached 425,000 active global customers, expanded financial assistance programs, generated renewable energy, reduced waste, and enhanced product sustainability. The company conducted a comprehensive double materiality assessment to prioritize initiatives and ensure operational resilience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
-
Rhea-AI Summary
Insulet (NASDAQ: PODD) announced plans to release its Q1 2024 financial results on May 9, 2024. The company will host a conference call at 4:30 p.m. (Eastern Time) to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
Rhea-AI Summary
Insulet (NASDAQ: PODD) appoints Ana Maria Chadwick as Executive Vice President, Chief Financial Officer and Treasurer. Ms. Chadwick brings extensive experience from top-tier organizations like Pitney Bowes and GE, enhancing Insulet's leadership team and financial capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
management
-
Rhea-AI Summary
Insulet Corporation (PODD) presents positive results from the OP5-003 Trial, showcasing improved glycemic outcomes with the Omnipod 5 Automated Insulin Delivery System. The trial demonstrated a 17.5% increase in time in range, reduced HbA1c levels, and improved patient-reported outcomes for individuals with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
-
Rhea-AI Summary
Insulet Corporation (PODD) to present new clinical evidence on Omnipod 5 Automated Insulin Delivery System at ATTD conference, showcasing positive outcomes and real-world evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences
Rhea-AI Summary
Insulet Corporation (PODD) reports 8th consecutive year of 20%+ revenue growth, with full year 2023 revenue reaching $1.7 billion, up 30.0% from the prior year. Omnipod revenue saw significant increases, with U.S. revenue up by 41.4% and International revenue up by 13.0%. Gross margin improved to 68.3%, operating income surged to $220.0 million, and net income reached $206.3 million. The company also delivered strong fourth quarter results, with revenue up by 37.9% to $509.8 million. Insulet highlighted key achievements, including launching Omnipod 5 integrated with Dexcom’s G7 sensor and receiving CE Mark approval for integration with Abbott’s Freestyle Libre 2 Plus sensor. The company projects revenue growth of 12% to 17% for 2024, with a focus on Omnipod and operating margin of approximately 13%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
-
Rhea-AI Summary
Insulet Corporation (PODD) to present at The Raymond James & Associates 45th Annual Institutional Investors Conference. The presentation will be on March 5, 2024, at 11:35 a.m. (Eastern Time). Investors can access the live webcast on investors.insulet.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) has received CE mark approval for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System. The system, the first and only tubeless hybrid closed loop system to achieve CE marking, is integrated with two CGM sensor brands, Abbott FreeStyle Libre and Dexcom. The Omnipod 5 integration is expected to be available in the United Kingdom and Netherlands in the first half of 2024, with additional markets to follow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
Rhea-AI Summary
Imperative Care, a medical technology company, announced the appointment of Chuck Alpuche as COO, Peter Griffin as SVP of Operations, Scott Elliott as CLO, and Daniel Davis as CSO. Alpuche brings 40 years of senior operational expertise and previously served as the Executive VP and COO of Insulet Corporation (NASDAQ: PODD). Griffin has over 35 years of manufacturing and product development experience, and Elliott joins with 30 years of experience as a legal advisor. Davis will oversee the growth and strategic initiatives of Imperative Care's businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Insulet Corp

Nasdaq:PODD

PODD Rankings

PODD Stock Data

17.33B
69.72M
0.38%
102.96%
4.09%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ACTON